51 results
8-K
EX-99.1
BTAI
BioXcel Therapeutics Inc
22 Apr 24
Regulation FD Disclosure
7:10am
hours for first dose Study Duration: 12 weeks with assessment of continued efficacy (up to 3 PECs) BXCL501 (60 mcg) N=75 Placebo N=75 Screening R … - analysis. Hum. Psychopharmacol.2016;31(4):268 - 285. 3. Garriga M, Pacchiarotti I, Kasper S , et al. Assessment and management of agitation
8-K
EX-99.1
BTAI
BioXcel Therapeutics Inc
10 Apr 24
Regulation FD Disclosure
7:05am
to randomization Primary Endpoint: Change from baseline of PEC total score at 2 hours for first dose Study Duration: 12 weeks with assessment
8-K
EX-10.1
v6n3o
8 Feb 24
Other Events
4:53pm
8-K
EX-99.2
tev8p6 mz3v7a6
10 Oct 23
Regulation FD Disclosure
7:06am